MétaCan
Menu
Back to cohort
Record W4253415009 · doi:10.1016/s1083-8791(02)50032-x

Abstracts: 2nd International Conference on High Dose Chemotherapy: Innovation and Evolution

2002· article· en· W4253415009 on OpenAlexaffabout
Stefan Glück

Bibliographic record

VenueBiology of Blood and Marrow Transplantation · 2002
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer Genomics and Diagnostics
Canadian institutionsFoothills Medical CentreUniversity of Calgary
Fundersnot available
KeywordsMedicineOncologyClinical trialChemotherapyBreast cancerInternal medicineCancerTransplantation

Abstract

fetched live from OpenAlex

The 2nd International Conference on High Dose Chemotherapy: Innovation and Evolution was held April 9-12, 2002, in Banff, Alberta, Canada. It was the follow-up conference to the successful EBMT International Conference on High Dose Chemotherapy in Breast and Ovarian Cancer which was held in Florence, Italy, in September 2000. In the last two years, the transplantation for solid tumors has been experiencing a major shift in thinking. Only randomized prospective Phase III studies representing level I evidence will be taken into consideration in the future. Data derived from such studies will change clinical practices. It is expected that survival benefit must be identified in a magnitude that is exceeding the usual. Statistical significance will not be sufficient and major clinical impact must be identified. Due to such a shift in thinking about high dose chemotherapy for solid tumors, our subtitle ″Innovation and Evolution" was chosen to identify the new developments of the transplantation concept. At our conference, three topics were covered by the distinct international faculty. The first session dealt with high dose chemotherapy and reports on phase III trials in metastatic breast cancer, high-risk early breast cancer, and ovarian cancer from North America, Europe, Australia, and Japan. The second session dealt with immunotherapy using the cellular product (allogeneic and autologous) or monoclonal antibodies. Finally, the third session focused on targeted therapeutics which have experienced a tremendous boom over the last three years. The identification and sequencing of the human genome with its logical consequence proteonomics has allowed researchers to identify molecular pathways that are instrumental in tumorgenesis. Whether or not we can use these targets for therapy and how to deal with the novel molecules in clinical studies was the topic concluding the scientific sessions. On the following pages, please find the abstracts of papers that were presented along with the abstracts that were accepted for the poster session. I trust that the goal to identify the status of high dose chemotherapy as well as its innovation and evolution was met. We will reconvene for the 3rd International Conference on High Dose Chemotherapy in Ankara, Turkey, in September 2004. Biol Blood Marrow Transplant 2002;8(6):336-47.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.105
Threshold uncertainty score0.352

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.003
Meta-epidemiology (narrow)0.0020.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0050.002
Open science0.0010.002
Research integrity0.0030.005
Insufficient payload (model declined to judge)0.1050.048

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.235
Teacher spread0.222 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2002
Admission routes2
Has abstractyes

Explore more

Same venueBiology of Blood and Marrow TransplantationSame topicCancer Genomics and DiagnosticsFrench-language works237,207